Stockscreener 앱 받기
22.04
2.13%
-0.48
시간 외 거래:
22.04
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Alto Neuroscience, Inc. (ANRO) and Pfizer (PFE) - The Globe and Mail
Alto Neuroscience Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Buy on Alto Neuroscience stock, $33 target - Investing.com
Alto Neuroscience: Advancing Precision-Psychiatry Pipeline and De-Risked Trials Support Buy Rating - TipRanks
Alto Neuroscience (NYSE:ANRO) Stock Price Down 3.6%Time to Sell? - MarketBeat
ANRO: ALTO-207 advances in TRD with rapid titration, strong efficacy, and key pipeline catalysts ahead - TradingView
Chardan Capital Reiterates "Buy" Rating for Alto Neuroscience (NYSE:ANRO) - MarketBeat
Alto Neuroscience (NYSE:ANRO) Price Target Raised to $22.00 - MarketBeat
$120M financing supports Alto’s precision neuroscience approach to TRD - The Pharmaletter
Alto raises $120m for resistant depression programme - pharmaphorum
Alto Neuroscience raises $120M to fund depression drug trial By Investing.com - Investing.com South Africa
Alto Neuroscience Reports Strong 2025 Financials, Advances Precision Psychiatry Pipeline with ALTO-207 Acquisition and Key Clinical Milestones - Minichart
Alto Neuroscience Secures $120 Million Private Placement to Fund Phase 3 Study of ALTO-207 for Treatment Resistant Depression - Minichart
Targeting depression, Alto Neuroscience raises $120 million - The Business Journals
Watkins Advises on Alto Neuroscience’s US$120 Million Private Placement Financing - Latham & Watkins LLP
Alto Neuroscience 2025 Annual Report: Precision Psychiatry Platform, Clinical Pipeline, and Intellectual Property Overview - Minichart
Alto Neuroscience, Inc. announced that it expects to receive $119.99969 million in funding from a group of investors - marketscreener.com
Jefferies raises Alto Neuroscience stock price target on pipeline By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Sets New 1-Year HighHere's Why - MarketBeat
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - marketscreener.com
Alto Neuroscience (ANRO) Reports FY25 Loss of $2.19/Share - AlphaStreet
Alto Neuroscience Announces $120 Million Private Placement Financing - TradingView
Alto Neuroscience raises $120M to fund depression drug trial - Investing.com
Alto Neuroscience Secures $120 Million Private Placement Financing - TipRanks
Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Alto Neuroscience (NYSE: ANRO) secures $120M PIPE to fund ALTO-207 - Stock Titan
ANRO: ALTO-207 acquisition and robust cash support multiple pivotal trials through 2028 - TradingView
Alto Neuroscience (NYSE: ANRO) outlines broad precision psychiatry pipeline and IP - Stock Titan
Alto Neuroscience 10-K: Net loss $63.24M, EPS $(2.19) - TradingView
Alto Neuroscience (NYSE: ANRO) posts 2025 loss but extends cash runway to 2028 - Stock Titan
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Yahoo Finance
Alto Neuroscience (ANRO) to Release Quarterly Earnings on Thursday - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading 7.3% HigherWhat's Next? - MarketBeat
Alto Neuroscience Stock Pre-Market (-7.0%): Geopolitical Tensions Spark Risk-Off Move - Trefis
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
VSE Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday - Intellectia AI
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Market Review: What are Alto Neuroscience Incs earnings expectationsPortfolio Profit Report & Low Drawdown Momentum Ideas - baoquankhu1.vn
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Fed Meeting: Is Alto Neuroscience Inc benefiting from interest rate changesDay Trade & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience (NYSE:ANRO) Stock Price Down 7.2%What's Next? - MarketBeat
Alto Neuroscience Stock Quote, Share Price, News and Analysis - Longbridge
Alto Neuroscience (NASDAQ: ANRO) CEO has shares withheld for taxes - Stock Titan
Alto Neuroscience (ANRO) CFO reports 2,806-share tax withholding - Stock Titan
ANRO: ALTO-207 and ALTO-101 advance with biomarker-driven trials and improved formulations for mental health - TradingView
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Benzinga
ARMISTICE CAPITAL, LLC Reduces Stake in Alto Neuroscience Inc - GuruFocus
March Presentations to Spotlight Alto Neuroscience's Clinical Strategy - AD HOC NEWS
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The Joplin Globe
Biotech investors get two chances to meet Alto Neuroscience in March - Stock Titan
Alto Neuroscience, Inc. (NYSE:ANRO) Slides in Biotech Indices - Kalkine Media
Alto Neuroscience (NYSE:ANRO) Trading Down 6.6%What's Next? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading Up 10%Here's What Happened - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):